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Synaptic communication requires the expression of functional
postsynaptic receptors that match the presynaptically released
neurotransmitter. The ability of neurons to switch the transmitter
they release is increasingly well documented, and these switches
require changes in the postsynaptic receptor population. Al-
though the activity-dependent molecular mechanism of neuro-
transmitter switching is increasingly well understood, the basis
of specification of postsynaptic neurotransmitter receptors match-
ing the newly expressed transmitter is unknown. Using a func-
tional assay, we show that sustained application of glutamate
to embryonic vertebrate skeletal muscle cells cultured before
innervation is necessary and sufficient to up-regulate ionotropic
glutamate receptors from a pool of different receptors expressed
at low levels. Up-regulation of these ionotropic receptors is
independent of signaling by metabotropic glutamate receptors.
Both imaging of glutamate-induced calcium elevations and West-
ern blots reveal ionotropic glutamate receptor expression prior to
immunocytochemical detection. Sustained application of gluta-
mate to skeletal myotomes in vivo is necessary and sufficient for
up-regulation of membrane expression of the GluN1 NMDA
receptor subunit. Pharmacological antagonists and morpholinos
implicate p38 and Jun kinases and MEF2C in the signal cascade
leading to ionotropic glutamate receptor expression. The results
suggest a mechanism by which neuronal release of transmitter
up-regulates postsynaptic expression of appropriate transmitter
receptors following neurotransmitter switching and may contrib-
ute to the proper expression of receptors at the time of initial
innervation.
neurotransmitter respecification | receptor specification | glutamate
receptors | development | plasticity
The expression of one or more neurotransmitters in a pre-synaptic neuron and expression of matching transmitter re-
ceptors in the postsynaptic cells are essential features of synapse
formation and function. Both initial genetic specification of
transmitter identity during development (1–3) and later trans-
mitter switching in response to sustained stimulation (4–9) raise
the question: How is expression of the appropriate postsynaptic
receptors achieved? The mechanisms producing transmitter re-
ceptor clustering have received extensive attention (10–14). In
contrast, the way in which the choice of receptor identity is de-
termined is less clear. Preprograming receptor identity would
appear to involve a substantial burden of information storage in
view of the large number of different transmitter receptors and
the myriad locations and contexts in which they are expressed
in the brain. Innervation-dependent specification of receptor
identity, through patterns of activity or factors released pre-
synaptically, would afford an alternative mechanism enabling
plasticity of expression.
Matching changes in neurotransmitter receptor expression
have been observed following neurotransmitter switching in de-
veloping and adult nervous systems, bringing this question into
sharp focus. In the peripheral nervous system, neurotransmitter
switching in motor neurons is accompanied by up-regulation of
functional receptors that were initially present at low levels and
matched the newly expressed transmitter (4, 15). Denervation
and reinnervation of adult skeletal muscle by glutamatergic
neurons lead to the appearance of functional neuromuscular
junctions expressing GluR1 and GluR2 (alias GluA1 and GluA2)
subunits, which are blocked by the AMPA receptor antagonist
GYKI 52466 (16, 17). In the central nervous system, the natural
developmental transmitter switch from GABA to glycine in the
auditory nervous system is accompanied by alterations in the
properties of postsynaptic receptors (18, 19). Changes in illumi-
nation during development or in photoperiod in the adult lead to
changes in the numbers of neurons expressing dopamine in the
hypothalamus that are accompanied by corresponding up- or
down-regulation of dopamine receptor expression in postsynaptic
neurons (5, 7).
Here, we analyze the mechanism by which changes in the class
of postsynaptic neurotransmitter receptor can be regulated in the
developing postsynaptic cell. We find that sustained exposure to
the transmitter glutamate is both necessary and sufficient for the
up-regulation of ionotropic glutamate receptors in Xenopus
striated skeletal myocytes in culture and in vivo, investigated with
calcium imaging, Western blot, and immunocytochemistry. We
identify components of a signaling cascade that are necessary for
expression of these receptors. Our findings suggest a process by
which classes of postsynaptic transmitter receptors are initially
up-regulated at newly assembling neuronal synapses and a basis
for transmitter-receptor matching in response to transmitter
switching.
Significance
Neurotransmitter switching generally involves replacement
of an excitatory transmitter with an inhibitory transmitter
or vice versa and has been linked to changes in animal be-
havior. There are corresponding switches in postsynaptic
receptors that enable continued function of the circuit, but
the mechanism by which receptor expression is regulated
in this context was unknown. Sustained exposure to the
neurotransmitter glutamate during development is both
necessary and sufficient for the upregulation of ionotropic
glutamate receptors in vertebrate striated skeletal muscle
cells. This finding suggests a basis by which neurotransmitter
release up-regulates expression of matching receptors at
newly formed synapses during development of the nervous
system and in response to neurotransmitter switching at
established synapses.
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Results
Signaling through Ionotropic Glutamate Receptors Is Necessary and
Sufficient to Induce Glutamate Sensitivity of Myocytes in Cell Culture.
We first investigated the basal glutamate sensitivity of embryonic
trunk myocytes cocultured with neurons prior to neuronal in-
nervation. Cultures were grown in medium containing 2 mM
extracellular calcium for 18–24 h (1.5–1.7 d of development),
rinsed, and loaded with Fluo-4 AM (20). The glutamate con-
centration in the synaptic cleft is estimated to achieve millimolar
levels (21), suggesting that these were appropriate concentra-
tions with which to test myocyte sensitivity. Twenty percent of
acetylcholine-sensitive myocytes uncontacted by neurons dem-
onstrated increased calcium fluorescence in response to local
superperfusion of a test concentration of 5 mM glutamate in
2 mM calcium medium in imaging experiments (Fig. 1 A–C).
Myocytes rarely responded to a second pulse of glutamate,
perhaps as a result of desensitization or internalization of re-
ceptors (22–24). Because the percent of neurons expressing
glutamate as a neurotransmitter increases 3-fold when neurons
are cultured in the absence of extracellular calcium (4), we next
grew neuron-myocyte cocultures for 18–24 h in 0 mM instead of
2 mM calcium medium. Now ∼40% of noncontacted myocytes
were sensitive to glutamate when loaded with Fluo-4 AM and
tested in the presence of 2 mM calcium during imaging (Fig. 1C;
see also ref. 15). The presence of calcium increases neuronal
activity that is further enhanced by veratridine (1 μM), reducing
neuronal expression of glutamate (4) and the incidence of
glutamate-responsive myocytes. Myocytes grown in the absence
of neurons are unaffected by culture condition and have a similar
baseline incidence of glutamate sensitivity as control neuron-
myocyte cultures, since myocyte activity is endogenously gener-
ated in the absence of innervation and unaltered by the presence
of calcium or veratridine (15, 25). These results suggested that
glutamatergic neurons could be signaling to myocytes, triggering
an increase in sensitivity.
To test the hypothesis that the stimulus promoting increased
sensitivity to glutamate is glutamate itself, signaling through low
levels of endogenous glutamate receptors, we investigated the
ability of exogenously applied glutamate to affect glutamate
sensitivity of myocytes. Myocytes were grown in the absence of
neurons for 18–24 h in 2 mM calcium medium containing dif-
ferent concentrations of glutamate and tested in the presence
of 2 mM calcium medium. These myocytes exhibited dose-
dependent changes in the incidence of sensitivity to chronic ex-
ogenous glutamate (SI Appendix, Fig. S1A). The incidence of
glutamate sensitivity increased from 20 to 60% as glutamate was
raised from 0.1 to 1 or 10 μM and then decreased (Fig. 1D and SI
Appendix, Fig. S1A). One micromolar glutamate was selected for
chronic stimulation in subsequent experiments. This concentra-
tion is much lower than the test concentration and is unlikely to
induce full AMPA or NMDA receptor desensitization (26, 27).
We next applied glutamate receptor antagonists together
with 1 μM glutamate in 2 mM calcium medium for 18–24 h to
determine which receptors are required to achieve this increase
in glutamate sensitivity. Pharmacological blockade of either
NMDA or AMPA receptors alone, with 50 μM AP5 or 15 μM
NBQX, was ineffective in abrogating the enhanced incidence of
sensitivity resulting from 1 μM glutamate exposure. However,
simultaneous application of both antagonists was sufficient to
fully block the increase from 20 to 60% incidence (Fig. 1D). The
incidence of myocyte responses to 5 mM glutamate after 1 μM
exposure for 18–24 h was reduced to 10% when cultures were
treated with AP5 and NBQX. Application of ionotropic receptor
agonists AMPA or NMDA alone or in combination (both at
1 μM) also enhanced the incidence of myocyte glutamate sen-
sitivity (SI Appendix, Fig. S1B). These results suggest that the
application of the transmitter (glutamate) alone, acting through
Fig. 1. Glutamate signaling through ionotropic receptors is necessary and sufficient to induce glutamate sensitivity of cultured myocytes. (A) Glutamate-
induced Fluo-4 AM fluorescence intensity in acetylcholine-sensitive myocytes (arrowheads) in response to neurotransmitter superfusion of a neuron-myocyte
coculture. (B) Digitized fluorescence of six myocytes in response to 5-s superfusion with 5 mM glutamate + 3 μM pancuronium or 1 μM acetylcholine following
18–24 h exposure to 1 μM glutamate in 2 mM Ca2+ culture medium. Traces are offset for clarity. (C) The incidence of glutamate sensitivity of myocytes in
neuron-myocyte culture depends on the culture medium. Basal sensitivity in neuron-myocyte cultures in 2 mM Ca2+ increased in the absence of Ca2+ that
increases the incidence of glutamatergic neurons but did not decrease significantly in the presence of 1 μM veratridine that decreases the incidence of
glutamatergic neurons, ANOVA with Tukey’s range test [F(2, 25) = 7.947]. Myocytes grown in the absence of neurons are unaffected by culture condition. (D)
The combination of 50 μM AP5 and 15 μM NBQX, but not either inhibitor alone, decreased incidence of glutamate responses in myocyte-only cultures grown
in the presence of 1 μM glutamate. ANOVA [F(4, 100) = 13.37, P < 0.0001] with Dunnett’s post hoc test. (C and D) n ≥ 8 cultures per group with 8–10 myocytes
per culture. Values are mean ± SEM, **P < 0.01, ***P < 0.001, ****P < 0.0001. See also SI Appendix, Figs. S1 and S2.
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ionotropic receptors, is both necessary and sufficient to induce a
significant increase in the incidence of myocyte sensitivity to
glutamate. The results indicate that glutamate recruits glutamate
sensitivity and that the responses that have been recruited are
mediated by ionotropic glutamate receptors. Analysis of Western
blots for GluN1 and GluA1 confirms up-regulation of NMDA
receptors at 1.5 d in vitro. (SI Appendix, Fig. S2 A and B).
Metabotropic Glutamate Receptors Do Not Stimulate Glutamate-
Induced Sensitivity of Myocytes In Vitro. The activity or surface
expression of ionotropic glutamate receptors (iGluRs) can be
modulated by activation of metabotropic glutamate receptors
(mGluRs) in conjunction with or independent of iGluR activa-
tion (28–31), and mGluRs have been reported on skeletal muscle
(32, 33). Therefore, mGluRs could mediate the effects of exoge-
nous glutamate on the glutamate sensitivity of myocytes together
with iGluRs. To determine whether the effects of glutamate on
myocyte glutamate sensitivity were mediated by metabotropic re-
ceptors, we tested the contributions of mGluRs to myocyte glu-
tamate sensitivity using class-specific agonists and antagonists.
Inhibition of group I mGluRs was sufficient to elevate baseline but
not the induced incidence of myocyte glutamate sensitivity. In-
hibition of group II or III mGluRs had no effect on baseline
or induced incidence of glutamate responses, suggesting their
downstream effectors do not mediate agonist-induced glutamate
sensitivity. Activation of each of the three classes of mGluRs
abrogated the incidence of glutamate-induced myocyte sensitiv-
ity (Fig. 2), despite differences in downstream effectors, in-
dicating that metabotropic glutamate receptors do not contribute
to the increased myocyte responses to glutamate.
Immunocytochemistry Does Not Detect Up-Regulated Glutamate
Receptors at Early Stages In Vitro. Immunohistochemically de-
tectable AMPA and NMDA receptor subunits GluA1 and GluN1
are expressed in Xenopus myocytes as early as 1.3 d of develop-
ment in vivo, before significant levels of clustered nAChRs appear
(15). Strikingly, we did not detect increases in immunocytochem-
ically detected GluN1 NMDA and GluA1 AMPA receptor sub-
units in fixed and permeabilized noncontacted myocytes in
neuron-myocyte cocultures in the absence vs. presence of 2 mM
calcium after 20 h in vitro (1.6 d of development) (SI Appendix,
Fig. S2 C–F), despite the changes in myocyte glutamate sensitivity
at this time. Small clusters were observed adjacent to nuclei or at
the extremities of the cells. Changes in receptor expression could
be due to increases in other glutamate receptor subunits; alter-
natively changes in GluN1 and GluA1 expression may be detected
optically with sensitive calcium imaging before changes are suffi-
ciently large to be observed by immunocytochemical examination,
perhaps because the newly expressed receptors are not clustered.
Glutamate Exposure Is Necessary and Sufficient To Induce Expression
of GluN1 in Myocytes In Vivo. To determine whether glutamate is
effective in increasing myocyte glutamate receptor expression
in vivo, we implanted agarose beads impregnated with 2 mM glu-
tamate or vehicle medium at 1 d of development to achieve sus-
tained local diffusion of agonist or control (4, 5, 34). Glutamate
exposure induced up-regulation of the GluN1 (NR1) NMDA re-
ceptor subunit at 2.8 d of development compared to levels achieved
with control beads loaded with medium, visualized immunohis-
tochemically (Fig. 3 A and B and SI Appendix, Fig. S3). Myocytes
were a day older when assayed in vivo than when assayed in culture,
likely contributing to the detection of receptors. Beads loaded with
10 μM AMPA and NMDA produced similar up-regulation of
GluN1 (Fig. 3 B and C). These increases were blocked when
NMDA and AMPA receptor blockers (0.5 mM AP5 and 0.15 mM
NBQX) were included with glutamate in the beads (Fig. 3 B andD).
Pharmacological Screening Suggests Components of the Signal
Transduction Cascade Required for Glutamate-Induced Glutamate
Sensitivity of Myocytes In Vitro. We returned to imaging calcium
elevations in cultured myocytes for pharmacological tests of the
role of activity-dependent kinases in increasing the percent of
glutamate-sensitive myocytes. Using specific antagonists, we
identified adenylate cyclase (AC), mitogen-activated protein ki-
nase kinase MEK1/2 (MAP2K1/MAP2K2), p38, and JNK as
downstream effectors of glutamate signaling that mediate agonist-
induced glutamate sensitivity (Fig. 4). Activation of group II
and III mGluRs typically leads to inhibition of AC (35, 36) and
suppresses glutamate-induced increased sensitivity to glutamate
(Fig. 2), suggesting that activation of AC may be downstream of
ionotropic receptor activation in glutamate-induced sensitivity.
Addition of 8-Br-cAMP (300 μM) to cultures increased myocyte
sensitivity to glutamate without sustained application of glutamate,
indicating that it may be part of the induction pathway that is not
additive with the effect of sustained glutamate application. In-
hibition of PKA, mTOR, or PKC significantly elevated baseline
glutamate sensitivity with no additional increase in the presence of
glutamate.
Morpholino Gene Knockdown Identifies Roles for p38 and JNK1 in
Glutamate-Induced Glutamate Sensitivity of Myocytes In Vitro and
Up-Regulation of GluN1 In Vivo. Morpholinos (MOs) are useful
tools for reducing expression of genes in vertebrate embryos (37,
38). We used MOs previously demonstrated to efficiently reduce
Fig. 2. Metabotropic glutamate receptors do not stimulate glutamate-
induced sensitivity of myocytes. Antagonists (Ant) to type I mGluRs (100 μM
AIDA) but not type II mGluRs (100 μM LY341495) or type III mGluRs (100 μM
MSOP) enhanced the incidence of glutamate sensitivity in the absence of ex-
ogenous glutamate (ANOVA with Dunnett’s post hoc test compared to control
F(6, 80) = 2.207; a, P < 0.05), with no additional gain in sensitivity in the presence
of glutamate (ANOVA F(6, 103) = 5.091; P < 0.05). The increased incidence of
glutamate sensitivity in response to glutamate was blocked in myocytes cultured
in the presence of agonists (Ago) for each class of mGluR (I, 100 μM CHPG; II,
100 μM LY354740; III, 20 μM L-AP4) (two-tailed unpaired t tests between glu+
and glu- pairs). n ≥ 8 cultures per group with 8–10 myocytes per culture. Values
are mean ± SEM. **P < 0.01, ****P < 0.0001.
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expression of their respective target in Xenopus embryos (SI
Appendix). Gene knockdown of p38 using MOs delivered in vitro
blocks agonist-induced sensitivity (Fig. 5A), confirming specific-
ity of the pharmacological inhibitor and implicating p38β (MAPK11)
and p38γ (MAPK12), but not p38α (MAPK14), as effectors. Be-
cause pharmacological inhibition of p38 suppressed agonist-induced
myocyte glutamate sensitivity, we tested the effect of glutamate
exposure on its phosphorylation status, which is indicative of its
activation state. Glutamate exposure induces a transient increase
in p38 phosphorylation after several hours (Fig. 5 B and C).
Consistent with this result, glutamate-mediated up-regulation of
GluN1 receptor subunit in vivo is blocked by simultaneous in-
hibition of p38β (Fig. 5 D and E). Calcium elevation in response
to glutamate receptor activation may activate p38, which then
activates the MEF2 transcription factor that binds to the GluN1
promoter (39, 40).
Targeted knockdown of JNK1 (MAPK8) using MOs delivered
in vitro blocks agonist-induced glutamate sensitivity (Fig. 6A),
confirming specificity of the pharmacological inhibitor and
identifying JNK1 as a critical effector. Because pharmacological
inhibition of JNK also abolished agonist-induced myocyte glu-
tamate sensitivity in vitro (Fig. 4A), we then examined its acti-
vation. Glutamate exposure induces a transient decrease in JNK
phosphorylation that returns to baseline after several hours (Fig.
6 B and C). Deactivation of JNK1 downstream of glutamate
receptor activation presumably reduces phosphorylation of fac-
tors that can inhibit transcription of GluN1. Glutamate-mediated
up-regulation of the GluN1 receptor subunit in vivo is blocked by
MO knockdown of JNK1 (Fig. 6 D and E).
Expression of the MEF2C Transcription Factor Is Necessary for Up-
Regulation of GluN1 In Vivo. The promoter for the NMDA re-
ceptor subunit GluN1 (NR1) contains a functional MEF2 rec-
ognition sequence (40, 41). Because MEF2C is a calcium-sensitive
transcription factor and a p38 target (39), MEF2C was a likely can-
didate to regulate glutamate-mediated up-regulation of the GluN1
receptor subunit. We tested the requirement forMEF2C in glutamate-
mediated GluN1 up-regulation in vivo. Targeting MEF2C with MOs
via agarose bead delivery abrogated the up-regulation of GluN1 in
response to glutamate (Fig. 7) supporting transcription-dependent
glutamate-mediated up-regulation of NMDA receptor subunits.
Discussion
Our results demonstrate that sustained exposure to the neuro-
transmitter glutamate during development is both necessary and
sufficient for the up-regulation of ionotropic glutamate receptors
in striated skeletal myocytes in vitro and in vivo. Calcium im-
aging of cultured myocytes provides functional evidence that is
substantiated by Western blots. Immunohistochemistry reveals
an increase in GluN1 in vivo. Myocyte-only cultures facilitated
calcium imaging that enabled detection of glutamate-induced
enhancement of glutamate sensitivity at 1 d in vitro and in-
creased expression of GluN1 by Western blot at 1.5 d in vitro.
These assays were both more sensitive than immunocytochem-
istry. The expression of calcium permeable AMPAR could also
contribute to early increases in glutamate sensitivity. Our find-
ings identify components of a signaling cascade that are necessary
for expression of glutamate receptors in developing myocytes and
suggest a mechanism by which up-regulation occurs. The results
Fig. 3. Glutamate signaling to ionotropic receptors is necessary and sufficient
to induce NMDA receptor up-regulation inmyocytes in vivo. (A) Agarose beads
loaded with drugs were implanted at stage 21 (22.5 h) and animals raised to
stage 40 (2.8 d). (B) Glutamate delivered by agarose beads stimulated an in-
crease in GluN1 immunoreactivity (% of labeled area within indicated borders)
in trunk myocytes. (C) Bead delivery of 10 μM AMPA and 10 μM NMDA also
induced expression of GluN1 in myocytes, ANOVA [F(2, 51) = 26.8] with
Dunnett’s post hoc test. (D) Bead delivery of 0.5 mM AP5 plus 0.15 mM NBQX
abrogated the glutamate-induced increase in GluN1 expression, ANOVA [F(3,
86) = 31.47]. n = 4 independent experiments for each graph. The lower right
number on each bar is the number of embryos examined. Values are mean ±
SEM. ****P < 0.0001. See also SI Appendix, Fig. S3.
Fig. 4. Inhibitors of adenylate cyclase and MAP kinases suppress glutamate-
induced glutamate sensitivity of myocytes. Coincubation of glutamate with
pharmacological inhibitors identified adenylate cyclase (AC; 5 μM SQ22536),
MEK1/2 (10 μM U0126), JNK (5 μM SP600125), and p38 (10 μM SB203580) as
mediators of the increase in glutamate sensitivity, ANOVA [F(9, 131) = 5.265]
with Tukey’s post hoc test. n ≥ 8 cultures per group and 8–10 myocytes per
culture. Values are mean ± SEM. ****P < 0.0001.
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provide a basis for neurotransmitter-receptor matching during
neurotransmitter switching at neuronal synapses during develop-
ment (5) and in the adult nervous system (7), as well as following
damage to mature neuromuscular synapses (9, 16, 17). The find-
ings may also be relevant to initial pairing of transmitter receptors
to neurotransmitters released at newly formed synapses.
Pharmacological and MO experiments suggest a model by which
glutamate acting through ionotropic receptors triggers several
converging pathways (Fig. 8). In this model, deactivation of JNK
alters phosphorylation of jun/ATF transcription factors that
bind to the AP-1 site in the GluN1 promoter (42). There appears
to be no reported direct connection between JNK deactivation
and NMDAR signaling, and JNK may act through an unknown
intermediary signal. Calcium influx through NMDARs can activate
MEF2 (43). Activation of AC generates cAMP that combines with
metabotropic actions of NMDARs and calcium to activate p38 (44,
45). p38 in turn increases MEF2 DNA binding and transactivation
(39). MEF2 requires the ubiquitous transcription factor SP1/3 for
efficient DNA binding to the GluN1 promoter (40). We propose
that the combined actions of these pathways create a feed forward
cycle that allows sustained exposure to glutamate to up-regulate
and maintain NMDA receptor subunit GluN1 expression. While
this model specifically addresses GluN1, the obligatory NMDA
receptor subunit, there may be a similar mechanism to up-regulate
other subunits to form functional receptors that these experiments
detected by increases in glutamate sensitivity.
Receptor-transmitter matching requires a low level of ex-
pression of multiple classes of postsynaptic receptors, for which
evidence has been obtained at neuromuscular junctions (15, 46).
This mechanism for ensuring matching of transmitters with their
cognate receptors avoids the need for prior specification of re-
ceptor localization, which would require encoding of large
amounts of information and likely be unresponsive to changes in
presynaptic neurotransmitter identity that occur during trans-
mitter switching. Cell adhesion molecules are known to play
Fig. 5. p38 is required for glutamate-induced glutamate sensitivity of
myocytes and up-regulation of NMDA receptors. (A) MO-mediated knock-
down of p38β or p38γ in vitro abolished the glutamate-mediated increased
sensitivity of myocytes to glutamate without affecting baseline sensitivity,
unpaired t tests between −glu and +glu pairs. n ≥ 5 cultures per group with
8–10 myocytes per culture. (B) Western blots of cultured myocytes exposed to
glutamate were probed for p-p38, p38, and actin. (C) The ratio of phosphor-
ylated versus total p38 increased briefly after glutamate exposure. Values are
from three experimental replicates, one-sample t tests to expected mean of 1
(control). (D) MO-mediated p38β knockdown in vivo eliminated the glutamate-
induced increase in GluN1 expression, ANOVA [F(3, 77) = 18.98] with Tukey’s
post hoc test. (E) Quantification of D. n = 4 independent experiments for each
bar. Values are mean ± SEM. *P < 0.05, ****P < 0.0001.
Fig. 6. JNK is required for glutamate-induced myocyte glutamate sensitivity
and NMDA receptor up-regulation. (A) MO-mediated knockdown of JNK1
in vitro abolished the glutamate-mediated increased sensitivity of myocytes
to glutamate (ANOVA F(3, 35) = 6.87 with Tukey’s post hoc test). n ≥ 8
cultures per group with 8–10 myocytes per culture. (B) Western blots of
cultured myocytes exposed to glutamate were probed for p-JNK, JNK, and
actin. (C) The ratio of phosphorylated to total JNK decreased temporarily
after glutamate exposure. Values are from three experimental replicates;
one-sample t tests to expected mean of 1 (control). (D) MO-mediated JNK
knockdown in vivo eliminated the effect of glutamate on increased GluN1
expression, ANOVA [F(3, 81) = 43.74] with Tukey’s post hoc test. (E) Quan-
tification of D. n = 4 independent experiments. Values are mean ± SEM. *P <
0.05, ***P < 0.001, ****P < 0.0001.
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roles in synaptogenesis at the neuromuscular junction (47). Our
results suggest that secreted factors are involved in postsynaptic
receptor expression and function. We predict that neurons ex-
press a reserve pool of transmitter receptors, normally expressed
at low density, the levels of which can be up-regulated in re-
sponse to release of transmitters by innervating nerve terminals.
Myocytes appear to constitutively express cholinergic receptors,
with glutamate up-regulating glutamate receptors under certain
circumstances (16, 17). Consistent with this picture, ACh receptors
are expressed even when the gene encoding choline acetyl-
transferase has been knocked out (48) and are required to maintain
the appropriate postsynaptic specializations of the motor endplates
(47). Glutamatergic signaling does not lead to down-regulation of
ACh receptors (Fig. 1 and SI Appendix, Fig. S1; refs. 9 and 17).
How many classes of transmitter receptors are myocytes capable of
expressing? Future work will determine whether the repertoire is
limited to a small group of receptors for classical transmitters such
as glutamate, GABA, and ACh, or whether receptors for biogenic
amines and peptides are also inducible by their ligands.
Materials and Methods
Animals.All animal procedureswereperformed in accordancewith institutional
guidelines and approved by the University of California San Diego Institutional
Animal Care and Use Committee. See SI Appendix for further details.
Cell Culture and Ca2+ Imaging.Myocytes were cultured for 18–24 h and loaded
with 1 μM Fluo-4 AM Ca2+ indicator (Invitrogen) and 0.01% Pluronic F-127
detergent (Molecular Probes). Images were acquired at 0.2 Hz for 10.5 min.
During imaging, cells were continuously superfused at 5 mL/min with 2 mM
Ca2+ medium. Five-second pulses of 5 mM glutamate dissolved in 2 mM
Ca2+ medium in the absence of exogenous glycine and presence of 3 μM
pancuronium or 1 μM acetylcholine were applied to test myocyte sensitivity
(15). Cells were considered glutamate- or ACh-sensitive when fluorescence
amplitude met or exceeded 20% of ΔF/F0, more than twice the SD of baseline
(Fig. 1B). Stock concentrations of drugs were added to culture medium and
washed out prior to Fluo-4 AM loading. See SI Appendix for details.
Western Blotting. Western blots were carried out on protein extracts from
myocytes cultured for 6, 20, or 38 h. For pMAPK time courses with glutamate
exposures <6 h, myocytes were allowed to differentiate morphologically for 6 h
and exposed to glutamate only during the final 45 min or 3 h before lysis. Anti-
bodies used were as follows: rabbit anti-GluR1 (GluA1) and mouse anti-NMDAR1
(GluN1) (Millipore), rabbit anti-p-p38, rabbit anti-p38 (Cell Signaling), rabbit anti-
pJNK (Promega), rabbit anti-JNK (Santa Cruz Biotechnology), and rabbit anti-actin
(Sigma-Aldrich). Blots were incubated with peroxidase-conjugated secondary an-
tibodies and bands were visualized using horseradish peroxidase chemi-
luminescence. See SI Appendix.
Bead Implantation. Spatial and temporal control of delivery of pharmacological
agents was achieved using agarose beads loadedwith 2mMCa2+mediumwith
or without drugs or vivo-MOs and implanted at stage 21 (5). Embryos were
processed for immunohistochemistry at stage 40. See SI Appendix.
Immunostaining. Culture immunocytochemistry and whole mount immuno-
histochemistry were performed as previously described (4, 15) using mouse
anti-NR1-CT (Millipore) or rabbit anti-GluR1 and fluorescent secondary an-
tibodies. Puncta larger than 0.75 μm, ∼1.5× the size of extracellular debris,
were counted as receptor clusters. The longest linear dimension of each
receptor cluster was measured. Skinned stage 40 larvae were incubated with
anti-NMDAR1 and imaged on a Leica SP5 confocal microscope. The percent
of GluN1-labeled area was determined by measuring the fraction occupied
by pixels of intensity at or below an empirically determined constant
threshold. See SI Appendix.
MOs. Cellmembrane-permeable vivo-MOs fromGeneToolsweredelivered in vitro
and in vivo. MOs targeting JNK1/MAPK8 [5′-TGCTGTCACGCTTGCTTCGGCTCAT-3′
(49)], p38α/MAPK14 [5′-GACGTAAGATTGATTGGATGACATA-3′ (50)], and MEF2C
[5′-CCATAGTCCCCGTTTTTCTGTCTTC-3′ (51)] were previously described. MOs
targeting p38β/MAPK11 (5′-CGCCCGCTCATCTTGCCCCGACCGG-3′) and p38γ/
MAPK12 (5′-CGAGTTCCCGGCAGGCTCCT-3′) were designed by GeneTools. A
standard control MO (5′-CCTCTTACCTCAGTTACAATTTATA-3′) and a 5-base
JNK1 mismatch (5′-TGCTGTGACCCTTCCTTCCGCTGAT-3′) were used to test
the specificity of MO effects.
Quantification and Statistical Analysis. Statistical tests used and number of
replicates are provided in each figure legend. Values were considered sig-
nificantly different at P < 0.05. See SI Appendix.
Data Availability Statement.All data for the paper are contained in the article.
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Fig. 7. MEF2 is required for NMDA receptor subunit up-regulation in vivo. (A)
GluN1 up-regulation is abolished by MEF2C MO-mediated knockdown. (B) Quan-
tification of A, n = 4 independent experiments. Values are mean ± SEM, ANOVA
[F(3, 75) = 21.67] with Tukey’s post hoc test. ****P < 0.0001.
Fig. 8. Model of neurotransmitter-receptor matching. Glutamate activation
of ionotropic receptors (iGluR) deactivates JNK through an unknown in-
termediary to regulate jun/ATF transcription factors that bind to the AP-1 site
in the GluN1 promoter. In parallel, iGluR stimulation leads to activation of
adenylate cyclase (AC) to generate cAMP that activates p38 in combination
with metabotropic actions of NMDARs. Ca2+ binding Ca2+-mediated activation
of PI3K, and p38-mediated phosphorylation of MEF2 dimers facilitate DNA
binding and transactivation. MEF2 requires SP1/3 for efficient DNA binding to
the GluN1 promoter. The combined actions of these pathways create a feed-
forward cycle that allows sustained exposure to glutamate to up-regulate and
maintain NMDA receptor subunit GluN1 expression.
Hammond-Weinberger et al. PNAS | February 25, 2020 | vol. 117 | no. 8 | 4373
N
EU
RO
SC
IE
N
CE
BI
O
PH
YS
IC
S
A
N
D
CO
M
PU
TA
TI
O
N
A
L
BI
O
LO
G
Y
1. S. Thor, J. B. Thomas, The Drosophila islet gene governs axon pathfinding and neu-
rotransmitter identity. Neuron 18, 397–409 (1997).
2. A. Pillai, A. Mansouri, R. Behringer, H. Westphal, M. Goulding, Lhx1 and Lhx5 main-
tain the inhibitory-neurotransmitter status of interneurons in the dorsal spinal cord.
Development 134, 357–366 (2007).
3. Y. Tanabe, C. William, T. M. Jessell, Specification of motor neuron identity by the
MNR2 homeodomain protein. Cell 95, 67–80 (1998).
4. L. N. Borodinsky et al., Activity-dependent homeostatic specification of transmitter
expression in embryonic neurons. Nature 429, 523–530 (2004).
5. D. Dulcis, N. C. Spitzer, Illumination controls differentiation of dopamine neurons
regulating behaviour. Nature 456, 195–201 (2008).
6. M. Demarque, N. C. Spitzer, Activity-dependent expression of Lmx1b regulates
specification of serotonergic neurons modulating swimming behavior. Neuron 67,
321–334 (2010).
7. D. Dulcis, P. Jamshidi, S. Leutgeb, N. C. Spitzer, Neurotransmitter switching in the
adult brain regulates behavior. Science 340, 449–453 (2013).
8. N. C. Spitzer, Neurotransmitter switching in the developing and adult brain. Annu.
Rev. Neurosci. 40, 1–19 (2017).
9. M. Bertuzzi, W. Chang, K. Ampatzis, Adult spinal motoneurons change their neuro-
transmitter phenotype to control locomotion. Proc. Natl. Acad. Sci. U.S.A. 115, E9926–
E9933 (2018).
10. L. S. Borges, Y. Lee, M. Ferns, Dual role for calcium in agrin signaling and acetylcholine
receptor clustering. J. Neurobiol. 50, 69–79 (2002).
11. K. A. Huebsch, M. M. Maimone, Rapsyn-mediated clustering of acetylcholine receptor
subunits requires the major cytoplasmic loop of the receptor subunits. J. Neurobiol.
54, 486–501 (2003).
12. I. Farhy-Tselnicker et al., Astrocyte-secreted glypican 4 regulates release of neuronal
pentraxin 1 from axons to induce functional synapse formation. Neuron 96,
428–445.e13 (2017).
13. S. Tadokoro, T. Tachibana, T. Imanaka, W. Nishida, K. Sobue, Involvement of unique
leucine-zipper motif of PSD-Zip45 (Homer 1c/vesl-1L) in group 1 metabotropic glu-
tamate receptor clustering. Proc. Natl. Acad. Sci. U.S.A. 96, 13801–13806 (1999).
14. J. F. Watson, H. Ho, I. H. Greger, Synaptic transmission and plasticity require AMPA
receptor anchoring via its N-terminal domain. eLife 6, e23024 (2017).
15. L. N. Borodinsky, N. C. Spitzer, Activity-dependent neurotransmitter-receptor
matching at the neuromuscular junction. Proc. Natl. Acad. Sci. U.S.A. 104, 335–340
(2007).
16. G. Brunelli et al., Glutamatergic reinnervation through peripheral nerve graft dictates
assembly of glutamatergic synapses at rat skeletal muscle. Proc. Natl. Acad. Sci. U.S.A.
102, 8752–8757 (2005).
17. M. Francolini et al., Glutamatergic reinnervation and assembly of glutamatergic
synapses in adult rat skeletal muscle occurs at cholinergic endplates. J. Neuropathol.
Exp. Neurol. 68, 1103–1115 (2009).
18. V. C. Kotak, S. Korada, I. R. Schwartz, D. H. Sanes, A developmental shift from
GABAergic to glycinergic transmission in the central auditory system. J. Neurosci. 18,
4646–4655 (1998).
19. S. Korada, I. R. Schwartz, Development of GABA, glycine, and their receptors in the
auditory brainstem of gerbil: A light and electron microscopic study. J. Comp. Neurol.
409, 664–681 (1999).
20. X. Gu, E. C. Olson, N. C. Spitzer, Spontaneous neuronal calcium spikes and waves
during early differentiation. J. Neurosci. 14, 6325–6335 (1994).
21. J. D. Clements, R. A. Lester, G. Tong, C. E. Jahr, G. L. Westbrook, The time course of
glutamate in the synaptic cleft. Science 258, 1498–1501 (1992).
22. F. Liang, R. L. Huganir, Coupling of agonist-induced AMPA receptor internalization
with receptor recycling. J. Neurochem. 77, 1626–1631 (2001).
23. S. Mangiavacchi, M. E. Wolf, Stimulation of N-methyl-D-aspartate receptors, AMPA
receptors or metabotropic glutamate receptors leads to rapid internalization of
AMPA receptors in cultured nucleus accumbens neurons. Eur. J. Neurosci. 20, 649–657
(2004).
24. G. N. Patrick, B. Bingol, H. A. Weld, E. M. Schuman, Ubiquitin-mediated proteasome
activity is required for agonist-induced endocytosis of GluRs. Curr. Biol. 13, 2073–2081
(2003).
25. M. B. Ferrari, J. Rohrbough, N. C. Spitzer, Spontaneous calcium transients regulate
myofibrillogenesis in embryonic Xenopus myocytes. Dev. Biol. 178, 484–497 (1996).
26. A. Robert, J. R. Howe, How AMPA receptor desensitization depends on receptor oc-
cupancy. J. Neurosci. 23, 847–858 (2003).
27. M. L. Mayer, L. Vyklicky, Jr, J. Clements, Regulation of NMDA receptor desensitization
in mouse hippocampal neurons by glycine. Nature 338, 425–427 (1989).
28. S. M. Ahn, E. S. Choe, Alterations in GluR2 AMPA receptor phosphorylation at serine
880 following group I metabotropic glutamate receptor stimulation in the rat dorsal
striatum. J. Neurosci. Res. 88, 992–999 (2010).
29. J. Cheng, W. Liu, L. J. Duffney, Z. Yan, SNARE proteins are essential in the potentia-
tion of NMDA receptors by group II metabotropic glutamate receptors. J. Physiol. 591,
3935–3947 (2013).
30. M. J. Wang et al., Group II metabotropic glutamate receptor agonist LY379268 reg-
ulates AMPA receptor trafficking in prefrontal cortical neurons. PLoS One 8, e61787
(2013).
31. J. Y. Lan et al., Activation of metabotropic glutamate receptor 1 accelerates NMDA
receptor trafficking. J. Neurosci. 21, 6058–6068 (2001).
32. A. Pinard, S. Lévesque, J. Vallée, R. Robitaille, Glutamatergic modulation of synaptic
plasticity at a PNS vertebrate cholinergic synapse. Eur. J. Neurosci. 18, 3241–3250
(2003).
33. K. K. Walder et al., Immunohistological and electrophysiological evidence that
N-acetylaspartylglutamate is a co-transmitter at the vertebrate neuromuscular junc-
tion. Eur. J. Neurosci. 37, 118–129 (2013).
34. D. Dulcis et al., Neurotransmitter switching regulated by miRNAs controls changes in
social preference. Neuron 95, 1319–1333.e5 (2017).
35. S. Nakanishi, Metabotropic glutamate receptors: Synaptic transmission, modulation,
and plasticity. Neuron 13, 1031–1037 (1994).
36. C. M. Niswender, P. J. Conn, Metabotropic glutamate receptors: Physiology, phar-
macology, and disease. Annu. Rev. Pharmacol. Toxicol. 50, 295–322 (2010).
37. J. Heasman, Morpholino oligos: Making sense of antisense? Dev. Biol. 243, 209–214
(2002).
38. J. E. Bestman, H. T. Cline, Morpholino studies in Xenopus brain development.
Methods Mol. Biol. 1082, 155–171 (2014).
39. J. Han, Y. Jiang, Z. Li, V. V. Kravchenko, R. J. Ulevitch, Activation of the transcription
factor MEF2C by the MAP kinase p38 in inflammation. Nature 386, 296–299 (1997).
40. D. Krainc et al., Synergistic activation of the N-methyl-D-aspartate receptor subunit 1
promoter by myocyte enhancer factor 2C and Sp1. J. Biol. Chem. 273, 26218–26224
(1998).
41. A. Zarain-Herzberg, I. Lee-Rivera, G. Rodríguez, A. M. López-Colomé, Cloning and
characterization of the chick NMDA receptor subunit-1 gene. Brain Res. Mol. Brain
Res. 137, 235–251 (2005).
42. G. Bai, J. W. Kusiak, Cloning and analysis of the 5′ flanking sequence of the rat
N-methyl-D-aspartate receptor 1 (NMDAR1) gene. Biochim. Biophys. Acta 1152, 197–200
(1993).
43. S. W. Flavell et al., Activity-dependent regulation of MEF2 transcription factors sup-
presses excitatory synapse number. Science 311, 1008–1012 (2006).
44. C. H. Chen, D. H. Zhang, J. M. LaPorte, A. Ray, Cyclic AMP activates p38 mitogen-
activated protein kinase in Th2 cells: Phosphorylation of GATA-3 and stimulation of
Th2 cytokine gene expression. J. Immunol. 165, 5597–5605 (2000).
45. S. Nabavi et al., Metabotropic NMDA receptor function is required for NMDA
receptor-dependent long-term depression. Proc. Natl. Acad. Sci. U.S.A. 110, 4027–
4032 (2013).
46. N. C. Spitzer, L. N. Borodinsky, Implications of activity-dependent neurotransmitter-
receptor matching. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 1393–1399 (2008).
47. J. R. Sanes et al., Development of the neuromuscular junction: Genetic analysis in
mice. J. Physiol. Paris 92, 167–172 (1998).
48. T. Misgeld et al., Roles of neurotransmitter in synapse formation: Development of
neuromuscular junctions lacking choline acetyltransferase. Neuron 36, 635–648
(2002).
49. H. Yamanaka et al., JNK functions in the non-canonical Wnt pathway to regulate
convergent extension movements in vertebrates. EMBO Rep. 3, 69–75 (2002).
50. E. Ohnishi et al., Nemo-like kinase, an essential effector of anterior formation,
functions downstream of p38 mitogen-activated protein kinase. Mol. Cell. Biol. 30,
675–683 (2010).
51. Y. Guo et al., Comparative analysis reveals distinct and overlapping functions of
Mef2c and Mef2d during cardiogenesis in Xenopus laevis. PLoS One 9, e87294 (2014).
4374 | www.pnas.org/cgi/doi/10.1073/pnas.1916600117 Hammond-Weinberger et al.
